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Sanitary pads for menstrual hygiene have a layered design consisting of a ﬂuid permeable surface
(topsheet), an absorbent core, and an impermeable backing with adhesive. Most sanitary pads employ
cellulose-based cores. This describes the safety evaluation of a menstrual pad with an emollient-treated
topsheet and a novel polymeric foam core. A quantitative risk assessment was performed, which
included: (1) toxicological evaluation of the raw material components; (2) quantitative exposure as-
sessments of pad constituents, accounting for the ﬂuid handling properties of the product and pertinent
conditions of use; and (3) risk characterization for exposure to raw materials (e.g., potential for skin
irritation, contact sensitization, or systemic effects, if relevant) and to the physical article itself (potential
effects on skin friction, etc.). No signiﬁcant risk of adverse effects was found. Five years of post-market
surveillance substantiates that the product is well-tolerated (1 health complaint reported per 2
million products shipped to market) and surpasses women's expectations for menstrual protection and
overall comfort and dryness. This report illustrates how the classical risk assessment paradigm, informed
by the impact of product design, functionality and pertinent use conditions, allowed the systematic
safety evaluation of a personal hygiene product with a novel, non-cellulosic absorbent foam core
technology.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Millions of women worldwide rely on disposable menstrual
pads and panty liners for feminine hygiene protection. Invented in
1896, disposable sanitary pads were ﬁrst successfully commer-
cialized in the United States in 1921. Most sanitary pads employ the
same basic design: a cellulose-based absorbent core placed be-
tween a ﬂuid permeable surface (topsheet) and a moisture-
impermeable backing (backsheet). Innovation was slow to this
product category: the 1970s brought the ﬁrst substantive
improvement, adding a panty-fastening adhesive to the backing to
replace traditional pins and belts. Over the next 25 years, signiﬁcant
innovations included apertured ﬁlm topsheets to keep the surface
of the pad cleaner and drier; wrap-around, side panty-shields
(“wings”) to reduce undergarment soiling; cellulosic cores with
superabsorbent gel particles for better protection in substantially
thinner pads; and the use of cloth-like perforated topsheets fornati, OH 45224, USA.
.
Inc. This is an open access article uimproved comfort and dryness. This article describes the safety
assessment process for our most signiﬁcant product innovation in
the category to date, the introduction of a thin, non-cellulosic,
absorbent foam core. The safety assessment process comprised an
exposure-based quantitative risk assessment on all product com-
ponents; analytical testing for residual monomers; and clinical
testing on components and/or the ﬁnal product to conﬁrm skin
compatibility. Post-market surveillance of global consumer expe-
rience further substantiates product safety in the marketplace. This
article illustrates how the risk assessment paradigm enabled the
rigorous safety evaluation of a menstrual pad with a novel absor-
bent material that represents a signiﬁcant departure from tradi-
tional cellulose ﬁber cores. Other safety evaluations (environmental
assessment, worker safety assessment) were followed but not
discussed here.2. Regulatory framework
Regulatory classiﬁcation of sanitary (menstrual) pads varies
globally. Some countries have stringent criteria; others subject this
product class to broadly applicable consumer product regulations.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sanitary pads as Class I medical device subject to manufacturing
controls and consumer complaint management. In Japan, sanitary
pads fall under the purview of the Pharmaceutical and Medical
Devices Agency. In the European Union and in Canada, sanitary
pads they are considered articles and are regulated as consumer
products. Although the speciﬁcs may vary among jurisdictions, a
human health risk assessment of new products and chemicals is a
fundamental expectation in all geographies that have regulatory
frameworks (Section 4 below).
3. Sanitary pad composition
The sanitary pad in this investigation has a conventional layered
design: a ﬂuid permeable surface (topsheet), an absorbent core, and
impermeable backing with adhesive (backsheet). Product compo-
nent composition is detailed in Table 1. In brief, the topsheet is a
polyethylene/polypropylene non-woven fabric bearing an emol-
lient ﬁnish; the core comprises a two-layer, low density, open-
celled, polyacrylate polymer foam; and the backsheet consists of
an impermeable pigmented polyethylene ﬁlm with a panty-
fastening adhesive. Scented versions of the pad contain a small
amount of perfume applied between the backsheet and the un-
dersurface of the core.
4. The safety assurance process
Scientiﬁc committees (NAS, 1983; SCCS, 2010), regulatory
agencies (ECHA, 2013; EPA, 2012; Gaylor et al., 1997) and other
authoritative bodies (WHO, 2010) promulgate a tiered risk assess-
ment approach to assessing chemical safety. The exposure-based
quantitative risk assessment (QRA) has four components:
 Hazard identiﬁcation (identifying the nature of potential
adverse effects based on the toxicological characteristics of the
chemicals or materials in question),
 Exposure characterization (quantifying the exposure to sub-
stances of toxicological interest for pertinent routes by deter-
mining the magnitude, duration and frequency of exposure
under relevant conditions of consumer use),
 Risk characterization (comparing these quantitative estimates
to safe benchmarks for which no signiﬁcant risk of adverse
health effects exists, incorporating a margin of safety [uncer-
tainty factor] where needed to extrapolate from experimental
conditions to those that occur in use), and
 Risk management (implementing approaches to further miti-
gate the possibility of adverse effects in the marketplace, e.g.,
post-market surveillance, product usage instructions,
cautionary labels, quality manufacturing expectations, etc.).
This fundamental model has been applied to the human safety
assessment of a variety of personal products, including absorbentTable 1
Composition of a sanitary pad with emollient-treated topsheet and absorbent foam core
Component Function
Topsheet Fluid permeable surface cover that is soft to the
skin and allows ﬂuid to penetrate
Emollient Potential comfort and skin moisturizing beneﬁts
Absorbent core Absorb and capture ﬂuids
Perfume Scent
Backsheet (printed) Moisture impermeable barrier
Adhesive Fasten pad to the undergarmentproducts such as infant diapers (Kosemund et al., 2009) and sani-
tary pads (Farage et al., 2004; Farage, 2006) as well as skin care
products and fragrances (Api et al., 2015; Bickers et al., 2003). For
each of these product categories, the risk assessment approach is
iterative, has been reﬁned to account for usage conditions relevant
to the product category in question and, when the product is an
article, to include toxicological, physical and other relevant addi-
tional endpoints associated with exposure to the physical article
itself.
As the sanitary pad in this investigation is a physical article,
individual product components as well as the ﬁnished product
were evaluated. An exposure-based QRAwas performed on product
components; this was supplemented by analytical and clinical
testing to conﬁrm the safety of potential residual monomers and
skin compatibility of the pad components as well as the ﬁnished
product itself.
4.1. Hazard identiﬁcation
The most relevant toxicological end-points for this product
category are acute, cumulative and mechanical skin irritation, the
induction of delayed contact hypersensitivity (contact sensitiza-
tion), and the potential for acute or subchronic effects from the raw
material components or residual chemicals, should it be possible
for toxicologically-signiﬁcant systemic exposures to occur.
4.2. Exposure assessment
Due to the layered pad design, three degrees of exposure exist to
its components: (1) direct skin contact (topsheet and emollient);
(2) indirect skin contact (absorbent core and perfume); and (3)
negligible skin contact (pigmented backsheet and adhesive) (Fig. 1).
4.2.1. Materials with direct skin contact
The non-woven polymeric topsheet and the emollient contin-
ually contact the skin, but only a fraction of the material will
transfer during use. In simulation studies, emollient transfer to the
skinwas found to be <20% (Farage, 2010). This 20% value is adopted
as a conservative estimate of the maximum proportion of applied
emollient that will transfer to the body. It is also used to conser-
vatively estimate maximum skin transfer of low molecular weight
topsheet ingredients or low level residuals that are intended to
remain on the pad, but may transfer during use and therefore
warrant conservative assessment.
4.2.2. Materials with indirect skin contact
Materials below the topsheet (the absorbent polymeric foam
core and the perfume, if pertinent) exhibit indirect skin contact.
Transfer of non-polymeric subsurface constituents requires a
vehicle (urine, menses). For dermal exposure to occur, low molec-
ular weight constituents of the raw materials must ﬁrst be solu-
bilized in the vehicle then released from the pad to the skin under.
Raw material composition
Perforated non-woven fabric of polypropylene/polyethylene ﬁbers
Petrolatum based formulation
Polymeric open-celled foam
Fragrance raw materials
Low density polyethylene ﬁlm with pigments
Polyaromatic/polyoleﬁnic block copolymers, hydrocarbon resins, mineral oil
Fig. 1. Pad components with respective consumer exposure.
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oratory analyses with simulated urine and menses, estimated
reﬂux values are <5% of ﬂuid loadings (proprietary data). This value
is used as a highly conservative estimate of exposure to subsurface
constituents by assuming their total mass is solubilized in the
vehicle.4.2.3. Materials with negligible skin contact
Constituents of the backsheet and the adhesive have no or
negligible skin contact and no exposure through rewet. Data from
historical experience, product integrity standards and analytical
leachability evaluation support the assumption for no or negligible
skin exposure to these materials.4.2.4. Quantitative exposure assessment
Parameters used in the quantitative exposure assessment are
based on the above assumptions and an understanding of men-
strual habits and practices (Table 2). Systemic exposures are esti-
mated on a body weight basis; the critical exposure for evaluating
skin sensitization risk is the dose per unit area of skin exposed
(Robinson et al., 2000). Quantitative exposures are estimated as
follows:Table 2
Parameters used in the quantitative exposure assessment of sanitary pad components.
Parameters Va
Raw material mass e g
Concentration of a constituent in the raw material e %
Frequency of use 5 p
Transfer to skin 20
Fluid transfer to skin from internal pad layers (known as rewet or reﬂux) 5%
Dermal absorption 10
Exposure duration 10
Body weight (female) 50
Pad or component surface area e c
a Assumes 100% of residual constituents in topsheet fabric transfer to the same degre
b Assumes 100% residual constituents in inner layers of pad are solubilized in absorbeSystemic exposure ðmk=kg=dÞ¼Raw material mass in pad ðgÞ
 constituent concentration in the raw material ð%Þ
 frequency of use ðpads=dÞexposure duration ð100%Þ
 transfer to skin ð%Þconversion to mg 106m=g
dermal absorption ð%Þ=body weight ðkgÞ
Dermal exposure

mg=cm2=d
¼Raw material mass in pad ðgÞ
 constituent concentration in the raw material ð%Þ
 frequency of use ðpads=dÞexposure duration ð100%Þ
 transfer to skin ð%Þconversion to mg 106m=g
dermal absorption ð%Þ=exposed skin surface area cm24.3. Risk characterization
4.3.1. Materials with direct skin contact e topsheet and emollient
The polypropylene/polyethylene topsheet is similar to other
nonwoven topsheets used in commercial sanitary pads with a long
history of safe use. The fabric allows ﬂuid to penetrate and become
trapped by the core. Due to its highmolecular weight and negligible
residuals, no systemic toxicity concerns exist for the topsheet.
The petrolatum-based emollient is composed of highly-reﬁned
components approved by various authoritative bodies for leave-onlues and units
/pad
(i.e., g constituent/100 g pad)
ads/day
% of surface-applied components (estimate for material with direct skin contact)a
of absorbed ﬂuid (estimate for materials with indirect skin contact)b
0% (unless dermal penetration data are available)
0%
kg
m2
e (worst-case).
d ﬂuid and transferred to skin through rewet.
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constituents also are generally recognized as safe for human con-
sumption (CFR, 2014b). The emollient ingredients have been in used
at comparable or higher levels in commercial cosmetic and personal
care products sold worldwide. A substantial margin of safety exists
compared to the established safe benchmarks (NoObservable Effect
Levels) for emollient constituents (proprietary data). No ingredients
have been associated with systemic effects such as mutagenicity,
teratogenicity or carcinogenicity. A conﬁrmatory human repeated
insult patch test (HRIPT, Shelanskimethod, described in Farage et al.,
2008; Gerberick et al., 1998; and Marzulli et al., 2004) was per-
formed on sections of topsheet bearing emollient in subjects who
perceived their skin to be sensitive. No discernible skin erythema
and no evidence for the induction of delayed contact hypersensi-
tivity were observed (Farage et al., 2008).
4.3.2. Materials with indirect skin contact e absorbent foam core
and perfume
The absorbent foam core is a stable, high-molecular weight
polyacrylate polymer with small amounts of emulsiﬁers and wet-
ting agents. The polymeric foam itself is biologically inert and non-
bioavailable due to its high molecular weight, therefore posing no
systemic toxicological concern. Analysis of residual monomers us-
ing aggressive extraction solvents (cyclohexane) revealed levels of
<200 ppm depending on the monomer in question, but undetect-
able levels (<4e7 ppm) with solvents that mimic in-use conditions
(artiﬁcial menses, physiologic saline, and 95% saline/5% ethanol).
Based on the QRA, no signiﬁcant risk of systemic effects exists from
worst-case hypothetical exposure to extractable residuals in the
foam (unpublished data).
Non-clinical studies for the purpose of regulatory registration
requirements were performed to conservatively assess the irrita-
tion and sensitization potential of the foam core extracts. Extracts
(95% saline/5% ethanol) showed no evidence of cytotoxic effects in
L929 cells (all scores 0) and no evidence of vaginal irritation in
rabbits (i.e., no difference between naïve, sham, vehicle or treat-
ment groups) (Table 3). No evidence of contact sensitization was
observed in the mouse local lymph node assay (LLNA) (Table 3).
Clinical studies on the foam core included a 21-day cumulative
irritation patch test as well as an HRIPT. Study methods (for theseTable 3
Non-clinical studies on extracts of an absorbent polymeric foam used in sanitary pads.
Study Test materials Protocol
Cytotoxicity assay
in murine L-929
cells
 Core extract
 (in 95% saline/5%
ethanol)
 Negative control
(solvent)
 Positive control (latex
rubber extract)
Five-day vaginal
irritation study
in rabbits
(naïve, sham, treatment
and vehicle groups)
 Core extract (in 95%
saline/5% ethanol)
 Naïve
 Sham instillation
 Vehicle control (95%
saline/5% ethanol)
Test materials instilled int
24-h intervals for 5 consec
Daily macroscopic assessm
signs of erythema, edema
Histopathology of cervicov
samples at study conclusio
Mouse Local Lymph Node
Assay (LLNA) for contact
sensitization
 Core extract (in 95%
saline/5%ethanol)
 Negative control
(acetone/olive oil, 4:1)
 Positive control (35%
hexylcinnamaldehyde)
The LLNA measures increa
proliferation of lymphocyt
auricular lymph nodes (wh
site of exposure, the mous
Proliferation is assessed by
bromodeoxyuridine (BrdU
incorporation into the DN
node cells by ﬂow cytomeand subsequent irritation and sensitization studies) were standard
predictive irritation patch tests and Shelanski etype HRIPT
methods, as described in Berger et al. (1982), Levin et al. (2004),
Marzulli et al. (2004), and Gerberick et al. (1998). Study methods
and results are summarized in Table 4. After 21 consecutive days of
exposure, the absorbent foam produced directionally (but not sta-
tistically) higher overall mean erythema scores than the non-
irritant control (physiologic saline) (1.22 vs. 0.97, respectively, on
a 0e4 scale, where a score of 0 denotes no apparent cutaneous
involvement and a score of 1 denotes either faint but deﬁnite er-
ythema or no erythema but faint dryness) (Farage et al., 2008). In
the HRIPT, the absorbent foam showed no evidence of irritation and
no evidence of contact sensitization (all scores zero through in-
duction and challenge phases) (Farage et al., 2008).
The perfume used in scented versions complies with the Inter-
national Fragrance Association (IFRA) safety standards for usage
limits, which are based on risk assessments by expert panels of the
Research Institute for Fragrance Materials (RIFM) (Api and Vey,
2008; Api et al., 2015; Bickers et al., 2003). All components of the
perfume are present at concentrations below the maximum limits
set by IFRA. An exposure-based risk assessment for contact sensi-
tization (Api et al., 2008; Gerberick et al., 2001) fromperfume in the
sanitary pad concluded that was sufﬁcientmargin of safety (1e500)
with respect to established sensitization benchmark doses.
4.3.3. Materials with negligible skin contact e backsheet and
adhesive
Polyethylene ﬁlm, a highmolecular weight polymerwidely used
in ﬂexible packaging, is not absorbed dermally. These ﬁlms and
associated pigments (resin-embedded or printed) have been used
extensively in personal hygiene products for many decades. The
panty-fastening adhesives are composed of high molecular weight,
polyaromatic-polyoleﬁn copolymers, hydrocarbon resins, and low
levels of antioxidants. Exposures to these components are virtually
nill and thus toxicologically insigniﬁcant.
4.3.4. Clinical studies on the sanitary pad
Cumulative irritation to the pad itselfwas assessed in 4-day patch
tests in subjects with normal skin (n¼ 17) or self-declared sensitive
skin (n¼ 15) and found to be comparable to the non-irritant (saline)Results Conclusion
Reactivity grades
Core extract: 0,0,0
Negative control: 0,0,0
Positive control: 4,4,4
No evidence of
cytotoxicity
ravaginally at
utive days.
ents for
or discharge.
aginal tissue
n.
 No mortality.
 No unusual signs or symptoms.
 No body weight differences between
groups.
 No macroscopic vaginal erythema,
edema or discharge in any group.
 Minimal histopathological changes
(all groups) not attributed to treatment.
Non-irritating.
sed
es in the
ich drain the
e ear).
determining
)
A of lymph
try.
STIMULATION INDEX
Negative control: none
Core extract concentrations:
 25%: 0.7
 50%: 0.8
 100%: 0.7
Positive control: 5.2
No evidence for the
induction of skin
sensitization
Table 4
Summary of skin compatibility program on sanitary pad with a polymeric foam absorbent core.
Study type Subjects Test products OMESa Summary of results
Irritationb
5-day study 31 Finished product 0.00 No evidence of irritation was noted for the
Finished Product. The ﬁnished product
was as mild as negative control.
0.9% Saline negative control 0.05
0.3% Sodium lauryl sulfate positive control 0.45
4-day study
Self-assessed sensitive skin
51 Finished product with Scent 0.37 Among self-declared sensitive skin subjects,
the Finished Product with Scent OMES was
similar to that of the negative control and
was well tolerated.
0.9% Saline negative control 0.33
0.3% Sodium lauryl sulfate positive control 1.77
4-day study
Normal skin
Self assessed sensitive skin
17 Finished Product 0.51 The Finished Product showed OMES
comparable to negative control in both the
normal and self-declared sensitive skin
populations.
0.9% Saline negative control 0.43
0.1% Sodium lauryl sulfate positive control 0.68
15 Finished product 0.35
0.9% Saline negative control 0.43
0.1% Sodium lauryl sulfate positive control 0.69
21-day study 30 Absorbent core 1.21 The Finished Product OMES was signiﬁcantly
less irritating than the absorbent core, ﬁnished
product without emollient and negative control.
Only clinically insigniﬁcant irritation observed
with Finished product without emollient.
Finished product 0.86
Finished product without emollient 1.11
0.9% Saline negative control 0.97
0.1% Sodium lauryl sulfate positive control 1.89
Contact sensitization
HRIPTc 103 Absorbent core No reactions indicative of skin sensitization
(Farage et al., 2008).
HRIPT 109 Finished product with scent No reactions indicative of skin sensitization.
Mechanical and chemical irritation
Behind the knee 13 Finished product The Finished Product showed erythema and
dryness scores comparable or directionally better
than currently marketed product. Results showed
no statistical difference in skin irritation potential
between the Finished Product and currently
marked product.
In-market control
Control articles noted in italics.
a OMES¼Overall Mean Erythema Score (Irritation tests, only). Sum of daily average skin grades divided by the number of study days.
b The standard predictive irritation protocol was used as described in Berger et al. (1982) and Levin et al. (2004). Patch tests employed 4-cm2 sections of the polymeric
absorbent core or the ﬁnished product moistened with 0.2e0.4 mL of physiologic saline. Occlusive patches were applied to the back or arm daily for 1, 4, 5, or 21 consecutive
days and skin reactions were evaluated by visual assessment after removal of each of the test material applications. Visual assessment was conducted by an expert grader
under a 100-W incandescent bulb using a previously described, standardized grading scale of ‘0’-‘4’ where ‘0’ is no apparent cutaneous involvement and ‘4’ is moderate-to-
severe spreading erythema and/or edema. Results are expressed as the OMES.
c HRIPT¼Human Repeated Insult Patch Test. The standard Shelanski-type HRIPT method was used as described by Gerberick et al. (1998) and Marzulli et al. (2004). The
induction phase consisted of nine 24-hr occlusive patches at a single site (outer aspect of upper arm) with a 24-hr rest between. The patch sites were graded for skin responses
prior to each application. After induction, there was a 14e17 day rest, followed by a 24-hr challenge patch applied on the original and alternate arm sites. Reactions were
scored 24- and 48-hr after removal of the challenge patch. Visual grading of the test sites used the standard scale with ‘0’ indicating no visible reaction and ‘3’ indicating
erythema. The presence of edema and/or papules, spreading, or vesicles was also noted.
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patch test in groups with normal skin. When sanitary pad samples
with and without the emollient were evaluated in a 21-day cumu-
lative irritationpatch test,mean erythema scores associatedwith the
emollient-treated pad were statistically lower than (and scores with
the untreated pad were comparable to) those associated with the
non-irritant control (Farage et al., 2008) (Table 4).
The combination of chemical and mechanical (frictional) irri-
tation was examined in a Behind-the knee (BTK) test, (ASTM, 2010;
Farage, 2008). In brief, the test pad and a reference commercial pad
with a history of safe use each were applied (with the topsheet
against the skin) to the popliteal fossa of one leg under an elastic
bandage for 6 h per day for 4 consecutive days. Skin irritation and
dryness were scored each day before application and 30e60 minafter removal of the product. Two studies were performed. The test
pad with foam core and emollient-treated topsheet exhibited
either comparable or directionally lower scores for erythema and
dryness than the reference product (Farage et al., 2008, 2009).
Finally, to further substantiate the absence of contact sensiti-
zation risk from the sanitary pad with perfume, an HRIPT was
performed on a scented version of the product (Table 4). No evi-
dence of contact sensitizationwas observed, further conﬁrming the
skin compatibility of the scented pad.
5. Post-market surveillance
Manufacturers employ post-market surveillance to monitor
consumers' experience and satisfaction, to further substantiate safe
K.E. Woeller, A.E. Hochwalt / Regulatory Toxicology and Pharmacology 73 (2015) 419e424424use in the marketplace, and to be alerted to any unanticipated is-
sues or unusual trends. Consumers provide feedback through a toll-
free telephone number printed on the package, by letter, and
increasingly, through electronic media such as bulletin boards,
social media, and manufacturer's web sites. Health-related ques-
tions and comments are analyzed on a continual basis, with many
decades of post-market surveillance serving as a reference for the
types and frequencies of comments that can be expected for
different product categories.
The sanitary pad in this investigation was ﬁrst marketed in
2008. Between the fall of that year and spring 2013, over 1.3 billion
pads were shipped to the North America market alone. The fre-
quency of health-related comments (typically skin effects) was 1
health complaint per 2 million pads shipped. While nowidely-used
sanitary pad is devoid of minor irritation or discomfort complaints,
the exceedingly low level of complaints is testimony to the rigor of
the safety assurance process described herein.
6. Conclusion
This article describes a systematic, tiered approach for evalu-
ating the safety of a new sanitary pad with an emollient-treated
topsheet and a novel, non-cellulosic absorbent foam core. An
exposure-based QRA was performed on raw material components,
supplemented by clinical testing to conﬁrm the skin compatibility
of pad components and the product itself. Postmarket surveillance
further substantiates that the product is very well-tolerated and
surpasses most women's expectations for menstrual hygiene and
comfort. The low incidence of reported health effects further sup-
ports that the applied risk assessment approach is both effective
and appropriate at assuring that safe feminine hygiene products are
introduced into the marketplace. This report illustrates how the
classical risk assessment paradigm (ECHA, 2013; NAS, 1983),
tailored to the speciﬁc product application and conditions of use,
enabled the rigorous safety evaluation of a menstrual pad with
absorbent foam technology that represents a signiﬁcant departure
from traditional cellulose-based hygiene products.
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